Prothrombin Fragment 1+2, Thrombin- Antithrombin III-Complexes and Fibrinopeptide A in Spontaneously Clotting Whole Blood In Vitro

 

PDF Download Buy Article Permissions and Reprints

Summary

Previous in vitro studies using spontaneously clotting whole blood revealed thrombin formation and high fibrinopeptide A (FPA) concentrations measured during incubation time. This occurred in spite of normal concentrations of thrombin antagonists present in the blood of the healthy subjects examined. However, there are several reports showing that in vivo increased thrombin- anti thrombin III-complex (TAT) concentrations and relatively low FPA concentrations may occur e. g. in patients with (pre)thrombotic disorders. These in vivo findings indicate more effective thrombin inhibition by antithrombin III, with almost no fibrin formation. To find an explanation for the differences observed in vitro and in vivo, we extended the in vitro studies by measuring concentrations of prothrombin fragment 1 + 2 (F_{1 + 2}), TAT and FPA at several time points until 30 min. Our goal was to test whether thrombin at least initially is neutralized by antithrombin III, resulting in a lack of fibrin formation, either in the absence or in the presence of heparin (0.2 and 0.5 U/ml whole blood, respectively).

In the absence of heparin a simultaneous increase in the concentrations of F₁₊₂, TAT and FPA was observed. Thrombin was only partially neutralized by antithrombin III and large amounts of fibrin were formed. The addition of heparin virtually suppressed thrombin formation since the F_{1 + 2} concentration remained low. Moreover, the small amounts of thrombin formed were neutralized by antithrombin III to a greater extent than in the absence of heparin. Thus, in the presence of heparin less fibrin was produced as evidenced by significantly lower FPA concentrations.

Experiments using blood of two patients with antithrombin III deficiency showed that fibrin formation was not different from the healthy controls in spite of the significantly higher initial F_{1 + 2} concentration measured. During incubation, the patients tended to form more thrombin, of which proportionally less was neutralized by antithrombin III, and more fibrin as compared to the healthy controls. Heparin addition suppressed thrombin formation less efficiently.

• References

• 1 Lorenz R, Gebhart S, Heptner W, Classen M. In vitro studies of secretion of platelet factor 4 and generation of fibrinopeptid A in native whole blood. Thromb Res 1988; 50: 231-5
  CrossrefPubMedGoogle Scholar
• 2 Kaplan KL, Drillings M, Lesznik G. Fibrinopeptide A cleavage and platelet release in whole blood in vitro. J Clin Invest 1981; 67: 1561-8
  CrossrefPubMedGoogle Scholar
• 3 Prowse CV, Vigano S, Borsey DQ, Dawes J. The release of beta-thromboglobulin from platelets during the clotting of whole blood. Thromb Res 1980; 17: 433-42
  CrossrefPubMedGoogle Scholar
• 4 Shuman MA, Levine SP. Thrombin generation and secretion of platelet factor 4 during blood clotting. J Clin Invest 1978; 61: 1102-6
  CrossrefPubMedGoogle Scholar
• 5 Rybak ME, Lau HK, Tomkins B, Rosenberg RD. Relationship between platelet secretion and prothrombin cleavage in native whole blood. J Clin Invest 1981; 68: 405-12
  CrossrefPubMedGoogle Scholar
• 6 Shuman MA, Levine SP. Relationship between secretion of platelet factor 4 and thrombin generation during in vitro blood clotting. J Clin Invest 1980; 65: 307-13
  CrossrefPubMedGoogle Scholar
• 7 Estivals M, Pelzer H, Sie P, Pichon J, Boccalon H, Boneu B. Prothrombin fragment 1 + 2, thrombin-antithrombin III complexes and D-dimers in acute deep vein thrombosis: effects of heparin treatment. Br J Haematol 1991; 78: 421-4
  CrossrefPubMedGoogle Scholar
• 8 Yudelman IM, Nossel HL, Kaplan KL, Hirsh J. Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. Blood 1978; 51: 1189-95
  PubMedGoogle Scholar
• 9 Bartsch P, Haeberli A, Straub PW. Blood coagulation after long distance running: Antithrombin III prevents fibrin formation. Thromb Haemost 1990; 63: 430-4
  Article in Thieme ConnectPubMedGoogle Scholar
• 10 Herren T, Bartsch P, Haeberli A, Straub PW. Increased thrombin-antithrombin III complexes after one h of physical exercise. J Appl Physiol 1992; 73: 2499-504
  CrossrefPubMedGoogle Scholar
• 11 De Boer K, Ten Cate JW, Sturk A, Borm JJ J, Treffers PE. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol 1989; 160: 95-100
  CrossrefPubMedGoogle Scholar
• 12 Weiner CP, Kwaan H, Hauck WW, Duboe FJ, Paul M, Wallemark CB. Fibrin generation in normal pregnancy. Obstet Gynecol 1984; 64: 46-8
  PubMedGoogle Scholar
• 13 Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol 1981; 10: 369-90
  PubMedGoogle Scholar
• 14 Demers C, Ginsberg J, Henderson P, Ofosu FA, Weitz JI, Blajchman MA. Measurement of markers of activated coagulation in antithrombin III deficient subjects. Thromb Haemost 1992; 67: 542-4
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Schulman S, Tengborn L. Treatment of venous thromboembolism in patients with congenital deficiency of antithrombin III. Thromb Haemost 1992; 68: 634-6
  Article in Thieme ConnectPubMedGoogle Scholar
• 16 Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antithrombin-III. Lancet 1977; ii: 581-4
  PubMedGoogle Scholar
• 17 Marciniak E, Farley CH, De Simone PA. Familial thrombosis due to antithrombin III deficiency. Blood 1974; 43: 219-31
  PubMedGoogle Scholar
• 18 Pratt CW, Church FC. Antithrombin: Structure and function. Semin Hematol 1991; 28: 3-9
  PubMedGoogle Scholar
• 19 Pelzer H, Schwarz A, Stiiber W. Determination of human prothrombin activation fragment 1 + 2 in plasma with an antibody against a synthetic peptide. Thromb Haemostas 1991; 65: 153-9
  PubMedGoogle Scholar
• 20 Lau HK, Rosenberg JS, Beeler DL, Rosenberg RD. The isolation and characterization of a specific antibody population directed against the prothrombin activation fragments F₂ and F_{1 + 2} . J Biol Chem 1979; 254: 8751-61
  PubMedGoogle Scholar
• 21 Lau HK, Rosenberg RD. The isolation and characterization of a specific antibody population directed against the thrombin-antithrombin complex. J Biol Chem 1980; 255: 5885-93
  PubMedGoogle Scholar
• 22 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-6
  Article in Thieme ConnectPubMedGoogle Scholar
• 23 Lollar P, Owen WG. Clearance of thrombin from circulation in rabbits by high-affinity binding sites on endothelium. J Clin Invest 1980; 66: 1222-30
  CrossrefPubMedGoogle Scholar
• 24 Machovich R. Choices among the possible reaction routes catalyzed by thrombin. Ann NY Acad Sci 1986; 485: 170-83
  CrossrefPubMedGoogle Scholar
• 25 Carlson TH. Clearance of thrombin in vivo: significance of alternative pathways. Mol Cell Biochem 1986; 71: 97-105
  CrossrefPubMedGoogle Scholar
• 26 Bourin MC, Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. Biochem J 1993; 289: 313-30
  CrossrefPubMedGoogle Scholar
• 27 Preissner KT. Anticoagulant potential of endothelial cell membrane components. Haemostasis 1988; 18: 271-306
  PubMedGoogle Scholar
• 28 Parker KA, Tollefsen DM. The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation. J Biol Chem 1985; 260: 3501-5
  PubMedGoogle Scholar
• 29 Mc Guire EA, Tollefsen DM. Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells. J Biol Chem 1987; 262: 169-75
  PubMedGoogle Scholar
• 30 Bar-Shavit R, Eldor A, Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties. J Clin Invest 1989; 84: 1096-104
  CrossrefPubMedGoogle Scholar
• 31 Liu CY, Nossel HL, Kaplan KL. The binding of thrombin by fibrin. J Biol Chem 1979; 254: 10421-5
  PubMedGoogle Scholar
• 32 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91
  CrossrefPubMedGoogle Scholar
• 33 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619-23
  CrossrefPubMedGoogle Scholar
• 34 De Marco L, Mazzucato M, Masotti A, Fenton II JW, Ruggeri ZM. Function of glycoprotein Iba in platelet activation induced by alphathrombin. J Biol Chem 1991; 266: 23776-83
  PubMedGoogle Scholar
• 35 Shuman MA. Thrombin-cellular interactions. Ann NY Acad Sci 1986; 485: 228-39
  CrossrefPubMedGoogle Scholar
• 36 Bauer KA, Rosenberg RD. The pathophysiology of the prcthrombotic state in humans: Insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-50
  PubMedGoogle Scholar
• 37 Jesty J. The kinetics of inhibition of thrombin by antithrombin in the presence of components of the hemostatic system. Blood 1985; 66: 1189-95
  PubMedGoogle Scholar
• 38 Downing MR, Bloom JW, Mann KG. Comparison of the inhibition of thrombin by three plasma protease inhibitors. Biochemistry 1978; 17: 2649-53
  CrossrefPubMedGoogle Scholar
• 39 Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-74
  CrossrefPubMedGoogle Scholar
• 40 Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60: 457-62
  Article in Thieme ConnectPubMedGoogle Scholar
• 41 Ofosu FA, Sie P, Modi GJ, Fernandez F, Buchanan MR, Blajchman MA, Boneu B, Hirsh J. The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem J 1987; 243: 579-88
  CrossrefPubMedGoogle Scholar
• 42 Tollefsen DM, Blank MK. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-96
  CrossrefPubMedGoogle Scholar
• 43 Zucker MB, Katz IR. Platelet factor 4: Production, structure, and physiologic and immunologic action. Proc Soc Exp Biol Med 1991; 198: 693-702
  CrossrefPubMedGoogle Scholar
• 44 Bauer KA, Goodman TL, Kass BL, Rosenberg RD. Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin III deficiency. J Clin Invest 1985; 76: 826-36
  CrossrefPubMedGoogle Scholar
• 45 Nossel HL, Yudelman I, Canfield RE, Butler Jr VP, Spanondis K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53
  CrossrefPubMedGoogle Scholar
• 46 Marcum JA, Mc Kenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparin-like molecules bound to the endothelium. J Clin Invest 1984; 74: 341-50
  CrossrefPubMedGoogle Scholar
• 47 Ofosu FA, Modi GJ, Hirsh J, Buchanan MR, Blajchman MA. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides. Ann NY Acad Sci 1986; 485: 41-55
  CrossrefPubMedGoogle Scholar
• 48 Mitchell L, Piovella F, Ofosu F, Andrew M. α₂-Macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children. Blood 1991; 78: 2299-304
  PubMedGoogle Scholar